Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company, has released its financial results for the second quarter of 2025. As of June 30, 2025, the company reported cash and cash equivalents of approximately $21.6 million, down from $48.3 million at the end of 2024. Research and development expenses increased to $10.0 million from $9.2 million in the same period in 2024, primarily due to a rise in external services and supplies costs. In corporate updates, Senti Bio has completed the dose-finding phase and confirmed the recommended Phase 2 dose in its ongoing Phase 1 clinical trial of SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia $(AML.AU)$. The SENTI-202 program has been granted U.S. FDA Orphan Drug Designation for AML treatment. Additionally, the company received a $1.0 million tranche from a California Institute for Regenerative Medicines grant to advance the clinical development of SENTI-202. The leadership team was strengthened with the appointments of Bryan Baum to the Board of Directors and Dr. James B. Trager to the Scientific Advisory Board. Senti Bio continues to engage with the investor and scientific communities through various events and conferences, aiming to increase visibility and awareness of its innovations in next-generation cell and gene therapies.